Study to Evaluate Novel, Potent, Orally Administered and Gut-Selective pan-Janus Kinase (JAK) Inhibitor in Patients with Moderately to Severely Active Crohn's Disease
PR Newswire
DUBLIN, Nov. 20, 2018
PR Newswire
DUBLIN, Nov. 20, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey